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The mechanism whereby a reactivation of cell cycle in neurons causes cell death is beginning to be identified. In cellular models of Alzheimer's
disease, activation of a non-canonical pathway of DNA replication contributes to neuronal death. This pathway involves the repair enzyme DNA
polymerase-β, which is highly expressed in neurons of the Alzheimer's brain at early stages of the disease. Loading of DNA polymerase-β into the
replication forks generates a death signal, which involves the tumor suppressor p53. The increasing knowledge of the main actors of the unscheduled
DNA replication in neurons will pave the way for novel therapeutic interventions in Alzheimer's disease and other neurodegenerative disorders.
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Over a decade ago, Vincent and Davies first showed that cell
cycle activation occurs in Alzheimer's disease (AD) brain [1].
Many studies since then have substantiated the hypothesis that
aberrant reactivation of the cell cycle might cause neurodegen-
eration because postmitotic neurons that resume their cell cycle
tend not to divide, but die (reviewed in ref. [2]).
So far, the so-called ectopic cell cycle activation has been
investigated under pathological canditions, such as AD [2], mild
cognitive impairment [3], Parkinson's disease (PD) [4], fronto-
temporal dementia (FTD) [5 6], and amyotrophic lateral sclerosis
(ALS) [7–10]. Correlative data have begun to accumulate in animal
models of pathology, including APP-transgenic mouse models of⁎ Corresponding author. Department of Human Physiology and Pharmacol-
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doi:10.1016/j.bbadis.2006.10.016AD [11,12], agedmice expressing non-mutant human tau [13], and
Drosophila models of tauopathies [14]. All these reports have
pointed to cell cycle activation as a common effector of
neurodegeneration in several different diseases. Accumulating
evidence that cell cycle proteins are present in the healthy rodent
and human brains (reviewed in ref. [15]) has led to the recent notion
that the reawakening of the cell cycle in post-mitotic neurons
represents a regulatory failure of the physiological neuronal
functions of cell cycle proteins. Key components of the cell cycle
machinery such as the anaphase promoting complex and the core
proteins of the origin core complex have been implicated in the
development of synapses [16] and in the control of dendrite and
spine development [17], respectively. Thus, neurons might have
found the way to use a large part of the cell cycle apparatus to
control synaptic plasticity by decoupling the expression of cell
cycle proteins from DNA replication [15]. However, a significant
number of neurons undergo partial or full DNA replication in AD
brain, and this is not seen in control brains [18]. By studying the
biochemistry of the cell cycle in a tissue culture model of AD, we
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cycling neurons [19], and that these fail to avoid DNA replication
by involving a DNA replication enzyme that normally functions
outside the cell division, the DNA polymerase-beta [20,21].
These findings suggest a model of “cell cycle disregulation”
that is the central hypothesis of this review: a non-canonical
pathway of DNA replication is causally related to neuronal
death. Molecular targets strictly related to this process might
provide the key to neuronal-specific cell cycle inhibition, such
targets are described below.
2. Quiescence exit, DNA replication entry and apoptosis of
differentiated neurons in response to β-amyloid
Cultured neurons exposed to synthetic β-amyloid (Aβ) die by
apoptosis [22], thus recapitulating the distinct feature of degenerat-
ing neurons in AD brain [23]. Interestingly, Aβ-mediated neuronal
apoptosis requires cell cycle activation [19]. But, what is the nature
of the cell cycle observed in a differentiated neuron? In proliferating
cells, key factors are the cyclin (Cyc)/cyclin-dependent protein
kinase (CDK) complexes, which control the transition through the
different phases of the cycle [24]. Activation of CDK4–6 by the
cyclin partner, Cyc D, is involved in the progression of the mid G1
phase, activation of CDK2 by Cyc E and CycA controls G1/S
transition and S phase progression, whereas the Cyc B/CDK1
complex is the regulator of the G2/M transition [25]. This sequence
of events also occurs in neurons challenged with Aβ. Following
Aβ treatment of rat cortical neurons, we observed the induction of
Cyc D1 and the phosphorylation of retinoblastoma (the substrate of
Cyc D/CDK4–6 complexes), followed by the induction of Cyc E
and A. The treated neurons started DNA replication, but then
appeared to undergo apoptosis (Fig. 1). By means of FACS
analysis, which allows the simultaneous evaluation of S phase and
apoptosis, we found that blockade of the G1/S transition using a
cyclin D1 antisense or a dominant-negative mutant of CDK-2
prevented both Aβ-induced DNA replication and apoptosis [19].
These experiments, and other studies [26–28], confirm that
neurons can recruit constitutive CDKs and can also be induced
to express cyclins to reactivate the cycle. Most important, the
ectopic S phase is an obligatory step in the apoptotic pathway
evoked by Aβ [19,29]. The question that remains is how doesFig. 1. Aβ acts as a proliferative signal for differentiated cortical neurons,
driving them into the cell cycle. The cycle follows the typical sequence of events
observed in proliferating cell, but does not progress beyond the S phase.the ectopic S phase result in neuronal death. To answer this
question, we have looked for the mechanisms that allow a
differentiated neuron to replicate its DNA.
3. Activation of a non-canonical DNA replication pathway
in differentiated neurons by Aβ
In proliferating cells, sequential activation of DNA polymerase
(pol)-α, and -δ or -ε [30] mediates DNA replication. Polα, with its
associate primase activity, is unique among DNA pols because of
its ability to start de novo DNA replication. Polα is constituted by
four distinct proteins with molecular weight of 180, 70, 58 and
49 kDa. The p49 subunit has primase activity, whereas the p180
subunit harbors the DNA polymerase activity of pol-α. By
replacing polα, polδ and/or polε function as major replicative
DNA pols that extend the nascent DNA primers. A fundamental
characteristic of DNA replication in proliferating cells is that the
different polymerases function in a way that the onset of mitosis is
blocked while DNA is being synthesized or damaged [31]. While
polα keeps the cell cycle in check, polδ and polε correct replication-
related mismatch errors.
Other pols are able to bypass with high fidelity specific types
of DNA damage occurring during replication, but they replicate
undamaged DNAwith high infidelity [32]. One of these, polβ,
is a DNA repair enzyme expressed in postmitotic neurons [20
21]. Intriguingly, in cultured neurons, Aβ induces the over-
expression of the repair enzyme polβ in a cell-cycle dependent
manner [20]. This is atypical, because the expression of pol-β is
expected to be regulated by DNA damage and not by the
activation of the cell cycle. Moreover, Aβ induces the p49 and
p58 subunits of primase, but neurons that enter the S phase in
response to Aβ fail to express polα, which is essential for the
canonical DNA replication [20].
It appears that DNA pol-β has a causal role in Aβ-induced
DNA replication and neuronal death, as shown by knocking
down the enzyme or inhibiting its activity with dideoxycytidine
[20]. Thus, neurons are one of the few known cases in which
pol-β carries out de novo DNA synthesis, others being the DNA
endoreduplication of trophoblast cells [33] and bacteria
replication [34].
Among the replicative pols, polδ is expressed constitutively
by cultured neurons but is not further induced by Aβ. As
opposed to polβ inhibition, polδ blockade reduces Aβ-induced
DNA replication but not neuronal apoptosis, indicating that in
neurons some DNA replication is possibly mediated by polδ but
does not contribute to neuronal death [20,21]. Thereafter, we
have hypothesized that the activation of a non-canonical
pathway of DNA replication, which is mediated by polβ, is
causally related to neuronal death.
4. A central role for DNA pol-β in AD neurodegeneration
The studies cited above leave unanswered the question of
how the non-canonical enzymatic machinery activated by Aβ
contributes to generate a death signal in neurons. Recently, we
have found the way to study the nature of the replication forks in
cultured neurons challenged with Aβ. We have discovered that
Fig. 2. Aβ activates a non-canonical pathway of DNA replication in
differentiated cortical neurons. DNA primase, polβ, and polδ are sequentially
loaded at neuronal replication forks. Polδ is recruited at the replication forks
after polβ has been unloaded and the death signal has been triggered. The death
signal is elicited by the extension of replicated DNA that depends on BER
processes carried out by APE1 and polβ itself.
Drugs Targets
• CDK inhibitor
(e.g., flavopiridol)
• G1/S phase transition
• DNA pol-β inhibitors
(e.g., dideoxycytidine)
• Non-canonical DNA
replication
• APE-1 inhibitors
(e.g., methoxyamine)
• BER contributing to DNA
replication
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neuronal replication forks, where polβ possibly substitutes for
the missing polα. Intriguingly, the loading of the repair enzyme
polβ occurs independently of base-excision repair (BER)
processes, whereas the recruitment of the replicative enzyme
polδ relies in part on a process of BER carried out by the
apurinic/apyrimidinic endonuclease (APE-1/Ref-1) and, likely,
by polβ itself [21]. It is noteworthy that the inhibition of APE-1,
and therefore of the BER process, not only prevents the loading
of polδ at the replication forks, but also reduces the overall DNA
synthesis and apoptotic death induced by Aβ. Since the
component of DNA replication mediated by polδ does not
contribute to neuronal death [20], these data suggest that an
efficient BER allows polβ-mediated DNA replication to
p roceed up to the th re sho ld fo r dea th be fo re
polδ loading [21] (Fig. 2).
5. Conclusions
Recent studies carried out in autoptic brain species from AD
patients strengthens the hypothesis that polβ is causally
involved in AD neurodegeneration. Similarly to the phosphory-
lated retinoblastoma, polβ is detected in neurons from cases
with minor AD-related neuropathology [21]; therefore, likewise
cell cycle proteins, the enzyme seems to be involved early in the
pathogenesis of AD [3,35,36].
Overall data demonstrate that polβ is an essential component
of the DNA-replication machinery in Aβ-treated neurons. In
these neurons, the extension of DNA replication carried out by
pol-β, and dependent on BER processes, is critical for the
activation of a death signal [21] that is mediated by the tumour
suppressor protein, p53 [20]. According to this model, joined
DNA replication and repair decide whether and when neurons
die and might be responsible for the slow cycling of AD
neurons before death (2–3, 18).
In the attempt to put the control of the cell cycle into a
therapeutic perspective, we must consider that cytostatic drugs
that act as CDK inhibitors (e.g., mimosine and flavopiridol) and
are protective against Aβ-induced toxicity [19,20] have adverse
effects that might seriously limit their use [37]. Since polβcarries out a large component of DNA replication and apoptotic
death in neurons exposed to Aβ, selective inhibitors of polβ
might represent a key to neuronal-specific cell cycle inhibition
as opposed to classical antineoplastic agents.
Finally, the finding that APE-1 contributes to the overall DNA
replication and apoptotic death induced by Aβ points to
additional targets for intervention. The evidence that the
expression of APE-1 is increased in regions of neuronal injury
in the AD brain [38] strengthens the suggestion that APE-1
inhibitors [39] are candidates for potential AD treatment (Box 1).
Box 1
Potential cell cycle-related neuroprotectant agents.Acknowledgment
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